Clinical trial • Phase IV • Other

Misoprostol for Uterine fibroid

Phase IV trial of Misoprostol for Uterine fibroid.

Overview

Trial Therapeutic Area
Other
Trial Disease
Uterine fibroid
Trial Stage
Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
24-09-2024
First CTIS Authorization Date
19-12-2024

Trial design

Randomised, placebo (oral coated tablet) versus misoone (misoprostol) 400 µg oral tablet (single pre-operative dose as per product specification).-controlled Phase IV trial across 1 site in France.

Randomised
Yes
Comparator
Placebo (oral coated tablet) versus MisoOne (misoprostol) 400 µg oral tablet (single pre-operative dose as per product specification).
Target Sample Size
80
Trial Duration For Participant
30

Eligibility

Recruits 80 No vulnerable population selected; participants are adult females aged 18 to 43. Subject information and informed consent form documents are available (SIS-and-ICF). No specific assent procedures or other vulnerable-population consent arrangements are described..

Pregnancy Exclusion
Pregnancy, suspected ectopic pregnancy and breastfeeding women.
Vulnerable Population
No vulnerable population selected; participants are adult females aged 18 to 43. Subject information and informed consent form documents are available (SIS-and-ICF). No specific assent procedures or other vulnerable-population consent arrangements are described.

Inclusion criteria

  • {"criterion_text":"- Patient aged 18 to 43"}
  • {"criterion_text":"- Symptomatic myomas (hemorrhages, pain or infertility)"}
  • {"criterion_text":"- Indication for myomectomy by laparoscopy Fibroid ≤ 10cm or number ≤ 4 fibroids"}
  • {"criterion_text":"- Indication for myomectomy by laparotomy Fibroid > 10cm, Number > 4 fibroids"}
  • {"criterion_text":"- OTAU possible intraoperatively (Clip on uterine artery and Placement of a turnstile)"}

Exclusion criteria

  • {"criterion_text":"- History of major uterine surgery or myomectomy (excluding myomectomy by hysteroscopy)"}
  • {"criterion_text":"- Allergy to misoprostol"}
  • {"criterion_text":"- Patient on aspirin or anticoagulant"}
  • {"criterion_text":"- Patients with a hemostasis disorder"}
  • {"criterion_text":"- Patient with hypersensitivity to misoprostol and/or other prostaglandins or to any of the excipients of the product"}
  • {"criterion_text":"- Malnourished patients"}
  • {"criterion_text":"- Patients with hepatic or renal impairment"}
  • {"criterion_text":"- Pregnancy, suspected ectopic pregnancy and breastfeeding women."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Intraoperative blood loss measured in mL (volume in the suction and blood volumes in the compresses after weighing) according to the randomization group.","definition_or_measurement_approach":"Measured in mL: volume in suction plus blood volumes in compresses after weighing, compared by randomization group."}

Secondary endpoints

  • {"endpoint_text":"- Depending on the randomization group, compare the difference in hemoglobin pre- and post-operatively then at 1 month and hemoglobin level","definition_or_measurement_approach":"Difference in hemoglobin measured pre-operatively, post-operatively and at 1 month; comparison between randomization groups."}
  • {"endpoint_text":"- Depending on the randomization group, compare: Demographic characteristics of patients and fibroids: BMI, Age, Gesture, Parity, Ethnicity, Tobacco, Taking pre-operative hormonal treatment, Type of treatment.","definition_or_measurement_approach":"Collection and comparison of demographic and clinical variables (BMI, age, gravidity, parity, ethnicity, tobacco use, pre-op hormonal treatment, treatment type) by randomization group."}
  • {"endpoint_text":"- Depending on the randomization group, compare: Characteristics of myomas: Types of myomas (FIGO), Size of myomas, Number of myomas.","definition_or_measurement_approach":"Assessment and comparison of myoma characteristics (FIGO type, size, number) between groups."}
  • {"endpoint_text":"- Depending on the randomization group, compare the duration between taking the tablet and anesthetic induction then the incision","definition_or_measurement_approach":"Time interval (tablet intake to anesthetic induction and to incision) recorded and compared between groups."}
  • {"endpoint_text":"- Depending on the randomization group, compare the duration between incision or pneumoperitoneum and closure","definition_or_measurement_approach":"Operative time measured from incision or pneumoperitoneum start to closure; compared between groups."}
  • {"endpoint_text":"- Depending on the randomization group, compare the accounting for the number of RGCs transfused.","definition_or_measurement_approach":"Number of red blood cell concentrates (RGCs) transfused recorded and compared between groups."}
  • {"endpoint_text":"- Depending on the randomization group, compare the collection of early postoperative complications.","definition_or_measurement_approach":"Recording of early postoperative complications and comparison between groups."}
  • {"endpoint_text":"- Depending on the randomization group, compare : EVA at H+2, H+6 D1 M1.","definition_or_measurement_approach":"Pain (EVA/VAS) measured at H+2, H+6, Day 1 and Month 1 and compared between groups."}
  • {"endpoint_text":"- Depending on the randomization group, compare : Length of hospitalization in days.","definition_or_measurement_approach":"Length of hospital stay in days recorded and compared between groups."}
  • {"endpoint_text":"- Depending on the type of surgery compare the difference in hemoglobin pre- and post-operatively then at 1 month and hemoglobin level","definition_or_measurement_approach":"Difference in hemoglobin measured pre-op, post-op and at 1 month, compared according to surgical technique (laparoscopy vs laparotomy)."}
  • {"endpoint_text":"- Depending on the type of surgery compare the demographic characteristics of patients and fibroids: BMI, Age, Gesture, Parity, Ethnicity, Tobacco, Taking pre-operative hormonal treatment, Type of treatment.","definition_or_measurement_approach":"Demographic and clinical variables collected and compared by surgical technique."}
  • {"endpoint_text":"- Depending on the type of surgery compare the characteristics of myomas: Types of myomas (FIGO), Size of myomas, Number of myomas.","definition_or_measurement_approach":"Myoma characteristics (FIGO type, size, number) assessed and compared by surgical technique."}
  • {"endpoint_text":"- Depending on the type of surgery compare the duration between taking the tablet and anesthetic induction then the incision","definition_or_measurement_approach":"Time from tablet intake to anesthetic induction and incision measured and compared by surgical technique."}
  • {"endpoint_text":"- Depending on the type of surgery compare the duration between incision or pneumoperitoneum and closure.","definition_or_measurement_approach":"Operative time (incision/pneumoperitoneum to closure) measured and compared by surgical technique."}
  • {"endpoint_text":"- Depending on the type of surgery compare the accounting for the number of RGCs transfused.","definition_or_measurement_approach":"Number of RGCs transfused recorded and compared by surgical technique."}
  • {"endpoint_text":"- Depending on the type of surgery compare the collection of early postoperative complications.","definition_or_measurement_approach":"Early postoperative complications collected and compared by surgical technique."}
  • {"endpoint_text":"- Depending on the type of surgery compare EVA at H+2, H+6 D1 M1","definition_or_measurement_approach":"EVA/VAS pain scores at H+2, H+6, Day 1 and Month 1 compared by surgical technique."}
  • {"endpoint_text":"- Depending on the type of surgery compare the length of hospitalization in days.","definition_or_measurement_approach":"Length of hospital stay in days compared by surgical technique."}
  • {"endpoint_text":"- Intraoperative blood loss measured in mL (volume in aspiration and blood volumes in compresses after weighing) according to the randomization group and surgical technique.","definition_or_measurement_approach":"Measured intraoperative blood loss in mL (suction volume + blood in compresses after weighing) compared by randomization group and by surgical technique."}

Recruitment

Planned Sample Size
80
Recruitment Window Months
26
Consent Approach
Informed consent is obtained using Subject Information and Informed Consent Form documents (SIS-and-ICF) uploaded for the trial. Participants are adult females who provide their own consent. No specific languages, assent procedures, or remote consent processes are described in the available records.

Geography

Total Number Of Sites
1
Total Number Of Participants
80

France

Earliest CTIS Part Ii Submission Date
07-11-2024
Latest Decision Or Authorization Date
05-06-2025
Processing Time Days
210
Number Of Sites
1
Number Of Participants
80

Sites

Site Name
University Hospital Of Clermont-Ferrand
Department Name
Gynecologie Obstétrique
Contact Person Name
Anne-Sophie GREMEAU
Number Of Participants
80

Sponsor

Primary sponsor

Full Name
University Hospital Of Clermont-Ferrand
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
MisoOne 400 mikrogramų tabletės
Active Substance
Misoprostol
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Marketing authorisation present (marketingAuthNumber: LT/1/22/5077/003)
Starting Dose
400 Aµg
Dose Levels
400 Aµg
Maximum Dose
400 Aµg
Investigational Product Name
PLACEBO
Active Substance
PLACEBO
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
No marketing authorisation number specified
Starting Dose
0 mg
Dose Levels
0 mg
Maximum Dose
0 mg

Related trials

Other published trials that may interest you.